Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up – Here’s What Happened

Shares of Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) gapped up before the market opened on Monday . The stock had previously closed at $15.98, but opened at $17.06. Daiichi Sankyo shares last traded at $16.98, with a volume of 16,495 shares.

Analyst Ratings Changes

Separately, Zacks Research raised shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 5th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, Daiichi Sankyo presently has a consensus rating of “Hold”.

Daiichi Sankyo Price Performance

The company has a market cap of $31.33 billion, a price-to-earnings ratio of 17.89, a price-to-earnings-growth ratio of 2.95 and a beta of -0.17. The company has a fifty day simple moving average of $16.30 and a two-hundred day simple moving average of $18.28. The company has a quick ratio of 1.64, a current ratio of 2.42 and a debt-to-equity ratio of 0.18.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its quarterly earnings data on Monday, May 11th. The company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.18). The business had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.74 billion. Daiichi Sankyo had a return on equity of 15.75% and a net margin of 12.32%.Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. On average, equities research analysts anticipate that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.98 earnings per share for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.